Bone marrow composition features and possibilities of tumor involvement diagnosing in patients with classic Hodgkin’s lymphoma

Q4 Medicine
F. M. Abbasbeyli, P. A. Zeynalova, M. A. Vernyuk, A. A. Fedenko, T. Yu. Mushkarina, A. A. Melnikova, V. Yu. Kovalskaya, L. Yu. Grivtsova
{"title":"Bone marrow composition features and possibilities of tumor involvement diagnosing in patients with classic Hodgkin’s lymphoma","authors":"F. M. Abbasbeyli, P. A. Zeynalova, M. A. Vernyuk, A. A. Fedenko, T. Yu. Mushkarina, A. A. Melnikova, V. Yu. Kovalskaya, L. Yu. Grivtsova","doi":"10.17650/1818-8346-2023-18-3-84-91","DOIUrl":null,"url":null,"abstract":"Background. Classical Hodgkin’s lymphoma is a B-cell lymphoproliferative disease, the tumor substrate of which is Berezovsky–Reed–Sternberg cells, characterized by CD30, PAX-5, CD15 expression and the absence of CD3, CD45. In some cases, tumor cells express CD20. modern anticancer therapy has increased the survival probability for most patients, not only with early but also with advanced stages of classical Hodgkin’s lymphoma. Such successes are mainly due to the distribution of patients into prognostic groups and the choice of an appropriate treatment regimen. tumor infiltration of the bone marrow suggests assigning patients to the advanced stages group, followed by the choice of an intensive therapy program. Aim. To determine the bone marrow involvement frequency according to positron emission tomography combined with computed tomography (PET/CT), with 18 F-fluorodeoxyglucose (FDG) and bone marrow trephine biopsy (bmtb), to compare the results obtained with primary tumor immunophenotype and bone marrow cellular composition, and to identify of prognostic risk factors. Materials and methods. The study included 107 patients with newly diagnosed classical Hodgkin’s lymphoma, who underwent a diagnostic examination at the moscow research institute of oncology named after P. A. Herzen – a branch of the National Medical Research Center for Radiology and the “Lapino” clinical Hospital from 2015 to 2022, followed by anticancer therapy and further follow-up. Morphology of the primary tumor biopsy specimen in all patients and immunohistochemical (IHC) study using a wide panel of monoclonal antibodies (CD15, CD30, CD3, CD45, CD20, PAX-5 anti-gens; in some cases epstein–barr virus proteins expression) in most cases were performed. All patients underwent a morphological and / or IHC study of BMTB and the majority underwent aspiration biopsy and PET/CT with 18 F-FDG. Results. The most common histological variant of classical Hodgkin’s lymphoma was nodular sclerosis (86.9 %). The majority of patients (51.4 %) were assigned to the advanced stage prognostic group. bone marrow tumor infiltration was statistically significantly more frequently diagnosed during PET/CT with 18 F-FDG compared with the results of the BMTB – in 27.1 % and 12.1 % of cases, respectively (p < 0.05). when comparing the results of both diagnostic methods, it was found that in 17.1 % of cases, bone marrow infiltration, detected during PET/CT, was not confirmed by IHC examination of the trephine biopsy. In addition, it was found that the majority of cases with CD20 +/± and CD15 +/± expression in the primary tumor were observed in the group of patients without bone marrow involvement. when assessing the cellular composition of bone marrow aspirates, it was revealed that in patients with bone marrow tumor infiltration, an increase in cellularity and megakaryocytes number along with a decrease in the plasma cells number is observed. Conclusion. The results suggest further study of bone marrow immunomorphological features in order to identify prognostic factors and search for new therapeutic targets. a more extended analysis of bone marrow aspirate immunomor-phological characteristics using new modern diagnostic methods, minimal residual disease status as a surrogate marker seems to be relevant and necessary to confirm the depth of the antitumor response achieved. Detection of CD20 +/± - and cd15 +/± -Berezovsky–Reed–Sternberg cells according to primary tumor IHC analysis indicates a low probability of bone marrow tumor infiltration, but further analysis is required on a large clinical and laboratory material.","PeriodicalId":37536,"journal":{"name":"Oncogematologiya","volume":"40 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncogematologiya","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17650/1818-8346-2023-18-3-84-91","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background. Classical Hodgkin’s lymphoma is a B-cell lymphoproliferative disease, the tumor substrate of which is Berezovsky–Reed–Sternberg cells, characterized by CD30, PAX-5, CD15 expression and the absence of CD3, CD45. In some cases, tumor cells express CD20. modern anticancer therapy has increased the survival probability for most patients, not only with early but also with advanced stages of classical Hodgkin’s lymphoma. Such successes are mainly due to the distribution of patients into prognostic groups and the choice of an appropriate treatment regimen. tumor infiltration of the bone marrow suggests assigning patients to the advanced stages group, followed by the choice of an intensive therapy program. Aim. To determine the bone marrow involvement frequency according to positron emission tomography combined with computed tomography (PET/CT), with 18 F-fluorodeoxyglucose (FDG) and bone marrow trephine biopsy (bmtb), to compare the results obtained with primary tumor immunophenotype and bone marrow cellular composition, and to identify of prognostic risk factors. Materials and methods. The study included 107 patients with newly diagnosed classical Hodgkin’s lymphoma, who underwent a diagnostic examination at the moscow research institute of oncology named after P. A. Herzen – a branch of the National Medical Research Center for Radiology and the “Lapino” clinical Hospital from 2015 to 2022, followed by anticancer therapy and further follow-up. Morphology of the primary tumor biopsy specimen in all patients and immunohistochemical (IHC) study using a wide panel of monoclonal antibodies (CD15, CD30, CD3, CD45, CD20, PAX-5 anti-gens; in some cases epstein–barr virus proteins expression) in most cases were performed. All patients underwent a morphological and / or IHC study of BMTB and the majority underwent aspiration biopsy and PET/CT with 18 F-FDG. Results. The most common histological variant of classical Hodgkin’s lymphoma was nodular sclerosis (86.9 %). The majority of patients (51.4 %) were assigned to the advanced stage prognostic group. bone marrow tumor infiltration was statistically significantly more frequently diagnosed during PET/CT with 18 F-FDG compared with the results of the BMTB – in 27.1 % and 12.1 % of cases, respectively (p < 0.05). when comparing the results of both diagnostic methods, it was found that in 17.1 % of cases, bone marrow infiltration, detected during PET/CT, was not confirmed by IHC examination of the trephine biopsy. In addition, it was found that the majority of cases with CD20 +/± and CD15 +/± expression in the primary tumor were observed in the group of patients without bone marrow involvement. when assessing the cellular composition of bone marrow aspirates, it was revealed that in patients with bone marrow tumor infiltration, an increase in cellularity and megakaryocytes number along with a decrease in the plasma cells number is observed. Conclusion. The results suggest further study of bone marrow immunomorphological features in order to identify prognostic factors and search for new therapeutic targets. a more extended analysis of bone marrow aspirate immunomor-phological characteristics using new modern diagnostic methods, minimal residual disease status as a surrogate marker seems to be relevant and necessary to confirm the depth of the antitumor response achieved. Detection of CD20 +/± - and cd15 +/± -Berezovsky–Reed–Sternberg cells according to primary tumor IHC analysis indicates a low probability of bone marrow tumor infiltration, but further analysis is required on a large clinical and laboratory material.
经典霍奇金淋巴瘤患者骨髓组成特征及肿瘤累及诊断的可能性
背景。经典霍奇金淋巴瘤是一种b细胞淋巴增生性疾病,其肿瘤底物为Berezovsky-Reed-Sternberg细胞,以表达CD30、PAX-5、CD15而缺乏CD3、CD45为特征。在某些情况下,肿瘤细胞表达CD20。现代抗癌治疗提高了大多数患者的生存率,不仅是早期的,也包括晚期的经典霍奇金淋巴瘤。这样的成功主要是由于患者分布到预后组和选择适当的治疗方案。骨髓肿瘤浸润提示将患者分配到晚期组,然后选择强化治疗方案。的目标。根据正电子发射断层扫描联合计算机断层扫描(PET/CT)、18f -氟脱氧葡萄糖(FDG)和骨髓环磷石活检(bmtb)确定骨髓受累频率,将所得结果与原发性肿瘤免疫表型和骨髓细胞组成进行比较,并确定预后危险因素。材料和方法。该研究纳入了107名新诊断的经典霍奇金淋巴瘤患者,他们于2015年至2022年在莫斯科肿瘤研究所接受了诊断检查,该研究所是国家放射医学研究中心和“Lapino”临床医院的分支机构,以P. a . Herzen命名,随后接受了抗癌治疗和进一步随访。所有患者原发肿瘤活检标本的形态学和免疫组化(IHC)研究,使用广泛的单克隆抗体(CD15、CD30、CD3、CD45、CD20、PAX-5抗原);在一些病例中进行eb病毒蛋白表达,在大多数病例中进行。所有患者都接受了BMTB的形态学和/或免疫组化研究,大多数患者接受了18f - fdg的吸活检和PET/CT检查。结果。典型霍奇金淋巴瘤最常见的组织学变异是结节硬化(86.9%)。大多数患者(51.4%)被分配到晚期预后组。与BMTB -相比,18 F-FDG PET/CT诊断骨髓肿瘤浸润的频率分别为27.1%和12.1% (p <0.05)。对比两种诊断方法的结果发现,17.1%的病例在PET/CT检查中发现骨髓浸润,而在穿刺活检中免疫组化检查未证实。此外,我们发现原发肿瘤中CD20 +/±和CD15 +/±表达的病例多见于未累及骨髓的患者组。在评估骨髓抽吸液的细胞组成时,发现骨髓肿瘤浸润患者的细胞数量和巨核细胞数量增加,浆细胞数量减少。结论。结果提示进一步研究骨髓免疫形态特征,以确定预后因素和寻找新的治疗靶点。使用新的现代诊断方法对骨髓抽吸免疫生理特征进行更广泛的分析,最小残留疾病状态作为替代标记物似乎与确认抗肿瘤反应的深度相关且必要。原发性肿瘤免疫组化分析检测到CD20 +/±-和cd15 +/±- berezovsky - reed - sternberg细胞提示骨髓肿瘤浸润的可能性较低,但需要在大量临床和实验室材料上进一步分析。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Oncogematologiya
Oncogematologiya Medicine-Hematology
CiteScore
0.50
自引率
0.00%
发文量
67
审稿时长
10 weeks
期刊介绍: The main purpose of the Oncohematology journal is to publish up-to-date information on clinical, experimental and fundamental scientific research, diagnostics and treatment options, as well as other materials on all relevant issues in oncohematology. The journal’s objectives are to inform various specialists who provide advisory and therapeutic assistance to patients with oncohematological diseases about current advances, including the latest methods for the diagnosis and treatment of malignant blood diseases. The journal is an interdisciplinary scientific publication uniting doctors of various specialties ‒ hematologists, oncologists, surgeons, radiation therapists, intensive care specialist, pathologists, etc. ‒ to form an interdisciplinary therapy approach in order to improve the treatment efficacy of patients with hematological malignancies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信